Ovarian Cancer
Metastatic Adenocarcinoma
Female, 68 years
Patient Internal ID: 500181945
ICD-10 code
C56 Malignant Neoplasm of Ovary
Diagnosis (Incl. Metastases/Stage) and Year
October 2021
Ovarian Adenocarcinoma pT3cN1M0 G3 stage IIIC. BRAC2 (+) Gene mutation in Exon 17. Post operation (October 2001), Chemotherapy (2002). From 2006 disease progression: cT3cN2M1 stage IV. Progression seen in 2006, 2012, 2016, 2017, and 2019 with Metastasis in Left Lung and Abdomen. Disease progression (January 2020): Metastases in Left Lung, Abdomen.
Previous Treatment
Surgery (Hysterectomy), Chemotherapy (Cisplatin /Cyclophosphamide), Chemotherapy (Carboplatin/Paclitaxel), Chemotherapy (Cisplatin/Gemcitabine), Target therapy (Olaparib), Radiation Therapy, Chemotherapy (Topotecan), Chemotherapy (Gemcitabine).
Prognosis and Survival Expectation
The prognosis of advanced Ovarian Adenocarcinoma with BRAC2 mutation has a median survival of 23 months from diagnosis.
Treatment Provided
Autologous DCV (6 doses) and CIK (8 doses). Additionally, the patient received Umbilical Cord Blood Derived NK cells (24 doses) and Mistletoe Therapy.
Patient Survival/Condition and Year
Date of Review: 17/02/2024
The patient is alive and under active treatment with Chemotherapy (Gemcitabine). She has survived 23 years so far and 17 years since disease progression. It can be concluded that Immunotherapy , alongside Surgery and Chemotherapies, has extended patient survival by around 2 decades compared with median survival.
